Fresh Tracks Therapeutics, Inc, A Clinical-Stage Pharmaceutical Company Aiming To Disrupt Existing Treatment Paradigms By Developing Innovative, Differentiated Prescription Therapeutics For The Treatment Of Autoimmune, Inflammatory, And Other Debilitating Diseases, Has Announced Publication Of Data From Preclinical Studies Of Frtx-02, A Potential First-In-Class, Orally Bioavailable Dyrk1A Inhibitor, In The Journal Of Translational Autoimmunity. The Paper Shows Frtx-02 To Be A Potent And Selective Inhibitor Of Dyrk1A With The Potential To Restore Immune Homeostasis By Regulating Adaptive And Innate Immune System Responses In Models Of Various Autoimmune And Inflammatory Diseases.
